Clinical review report: Erenumab (Aimovig) (Novartis pharmaceuticals Canada Inc.) indication: for prevention of migraine in patients who have had at least four migraine days monthly
The objective of this review is to perform a systematic review of the beneficial and harmful effects of erenumab for the prevention of migraine in adults who have at least four migraine days per month
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
September 2020, 2020
|
Edition: | Version: Final (with redactions) |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of erenumab for the prevention of migraine in adults who have at least four migraine days per month |
---|---|
Physical Description: | 1 PDF file (163 pages) |